Clinical Outcomes with Pemetrexed-Based Systemic Therapy in RET-Rearranged Lung Cancers

被引：0
|
作者：
Drilon, Alexander [1 ]
Bergagnini, Isabella [1 ]
Delasos, Lukas [1 ]
Sima, Camelia S. [1 ]
Smith, Roger [1 ]
Somwar, Romel [1 ]
Riely, Gregory J. [1 ]
Kris, Mark G. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
ROS1 ALK KRAS; RET; pemetrexed; rearrangement;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ORAL03.05
引用
收藏
页码：S178 / S178
页数：1
相关论文
共 50 条
  • [31] Wide and Cystic Brain Metastases Reveal RET-Rearranged Non-Small-Cell Lung Cancers
    Facchinetti, Francesco
    Bozzetti, Francesca
    Gnetti, Letizia
    Minari, Roberta
    Crafa, Pellegrino
    Rebuzzi, Sara Elena
    Ferrara, Roberto
    Gruppioni, Elisa
    Capizzi, Elisa
    Giombelli, Ermanno
    Crisi, Girolamo
    Altimari, Annalisa
    Tiseo, Marcello
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 7
  • [32] Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer
    Lin, Jessica J.
    Kennedy, Elizabeth
    Sequist, Lecia V.
    Brastianos, Priscilla K.
    Goodwin, Kelly E.
    Stevens, Sara
    Wanat, Alexandra C.
    Stober, Lisa L.
    Digumarthy, Subba R.
    Engelman, Jeffrey A.
    Shaw, Alice T.
    Gainor, Justin F.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : 2027 - 2032
  • [33] RET-rearranged non-small-cell lung cancer and therapeutic implications
    Loh, Zoe
    Mitchell, Paul
    John, Thomas
    Arulananda, Surein
    INTERNAL MEDICINE JOURNAL, 2019, 49 (12) : 1541 - 1545
  • [34] Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1-and ALK-rearranged Lung Cancer With Adenosquamous Histology
    Patil, Tejas
    Nie, Yunan
    Aisner, Dara L.
    Camidge, David Ross
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [35] RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
    K Tsuta
    T Kohno
    A Yoshida
    Y Shimada
    H Asamura
    K Furuta
    R Kushima
    British Journal of Cancer, 2014, 110 : 1571 - 1578
  • [36] MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers.
    Somwar, Romel
    Smith, Roger
    Hayashi, Takuo
    Ishizawa, Kota
    Charen, Alexandra Snyder
    Khodos, Inna
    Mattar, Marissa
    He, Jie
    Balasubramanian, Sohail
    Stephens, Phil
    Lipson, Doron
    De Stanchina, Elisa
    Davare, Monika
    Miller, Vincent A.
    Riely, Gregory J.
    Rudin, Charles M.
    Kris, Mark G.
    Cheng, Emily
    Ladanyi, Marc
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
    Tsuta, K.
    Kohno, T.
    Yoshida, A.
    Shimada, Y.
    Asamura, H.
    Furuta, K.
    Kushima, R.
    BRITISH JOURNAL OF CANCER, 2014, 110 (06) : 1571 - 1578
  • [38] Targeting RET-rearranged non-small-cell lung cancer: future prospects
    Bronte, Giuseppe
    Ulivi, Paola
    Verlicchi, Alberto
    Cravero, Paola
    Delmonte, Angelo
    Crino, Lucio
    LUNG CANCER-TARGETS AND THERAPY, 2019, 10 : 27 - 36
  • [39] Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series
    Fricke, Jeremy
    Wang, Joshua
    Gallego, Natalie
    Mambetsariev, Isa
    Kim, Pauline
    Babikian, Razmig
    Chen, Bihong T.
    Afkhami, Michelle
    Subbiah, Vivek
    Salgia, Ravi
    CLINICAL LUNG CANCER, 2023, 24 (07) : 666 - 671
  • [40] Metastatic RET-Rearranged Lung Adenocarcinomas Treated with Alectinib: Retrospective Analysis of a Single Institution
    Ribeiro, M.
    Gongora, A.
    Oliveira, L.
    Alessi, J. V.
    Saccardo, K.
    Zucchetti, B.
    Barbosa, F.
    Muniz, D.
    Shimada, A.
    De Souza, C.
    Feher, O.
    Katz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S857 - S858
12345